Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4891
Source ID: NCT00869908
Associated Drug: Insulin Aspart
Title: Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication
Acronym: A1chieve®
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 2
Interventions: DRUG: insulin aspart|DRUG: insulin detemir|DRUG: biphasic insulin aspart
Outcome Measures: Primary: Number of serious adverse drug reactions and major hypoglycaemic events reported as serious adverse drug reactions, at baseline, 12 weeks and 24 weeks | Secondary: Evaluate the prescribing patterns and choice of insulin analogues in routine clinical practice, at baseline, 12 weeks and 24 weeks|Change in number of hypoglycaemic events, at baseline, 12 weeks and 24 weeks|Change in HbA1c, at baseline, 12 weeks and 24 weeks|Change in FPG (Fasting Plasma Glucose), at baseline, 12 weeks and 24 weeks|Change in PPG (postprandial glucose), at baseline, 12 weeks and 24 weeks
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: CHILD, ADULT, OLDER_ADULT
Phases:
Enrollment: 66726
Study Type: OBSERVATIONAL
Study Designs: Observational Model: |Time Perspective: p
Start Date: 2008-11
Completion Date: 2011-03
Results First Posted:
Last Update Posted: 2017-01-19
Locations: Novo Nordisk Investigational Site, Algiers, 16035, Algeria|Novo Nordisk Investigational Site, Prov. de Buenos Aires, B1636DSU, Argentina|Novo Nordisk Investigational Site, Dhaka, 1206, Bangladesh|Novo Nordisk Investigational Site, Beijing, Beijing, 100004, China|Novo Nordisk Investigational Site, Cairo, Egypt|Novo Nordisk Investigational Site, Bangalore, 560001, India|Novo Nordisk Investigational Site, Jakarta, 12520, Indonesia|Novo Nordisk Investigational Site, Teheran, Iran, Islamic Republic of|Novo Nordisk Investigational Site, Amman, 11844, Jordan|Novo Nordisk Investigational Site, Seoul, 137-920, Korea, Republic of|Novo Nordisk Investigational Site, Tripoli, Libyan Arab Jamahiriya|Novo Nordisk Investigational Site, Selangor Darul Ehsan, Malaysia|Novo Nordisk Investigational Site, Mexico City, Mexico|Novo Nordisk Investigational Site, Casablanca, 20000, Morocco|Novo Nordisk Investigational Site, Karachi, Pakistan|Novo Nordisk Investigational Site, Manilla, 1605, Philippines|Novo Nordisk Investigational Site, Moscow, 119330, Russian Federation|Novo Nordisk Investigational Site, Riyadh, 3542, Saudi Arabia|Novo Nordisk Investigational Site, Singapore, 307684, Singapore|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Tunisia, 1053, Tunisia|Novo Nordisk Investigational Site, Istanbul, 34335, Turkey
URL: https://clinicaltrials.gov/show/NCT00869908

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress